Biome Australia (BIO) Q3 2026 TU earnings summary

Executive summary

• Consumer sell-through surpassed 1 million boxes of Activated Probiotics on a rolling 12-month basis in Q3 FY26, a company first confirmed by independent pharmacy scan data.

• Activated Probiotics is the fastest-growing probiotic brand in Australian community pharmacy over the past 12 months, with Biome Daily approaching the number one position by both units and value.

• Fullscript Canada national launch commenced in Q3, opening North America's largest practitioner distribution channel.

• Net increase in cash at bank for Q3 FY26, closing at $3,387k.

• FY26 is expected to be profitable, subject to normal trading conditions.

Financial highlights

• Receipts from customers were $4.89 million for Q3 FY26 and $18.24 million for the nine months year-to-date.

• Net cash used in operating activities was $(1.24) million for Q3 FY26, but positive $0.92 million year-to-date.

• Cash and cash equivalents at quarter end were $3.39 million, up from $3.36 million in the previous quarter.

• 40%+ revenue growth reported for H1 FY26 versus the prior corresponding period.

• EBITDA for FY26 is on track for a transformational step-change relative to FY25.

Outlook and guidance

• Q4 FY26 outlook supported by an anticipated strong respiratory illness season, largest-ever brand investment, and Fullscript Canada launch.

• Immune health segment expected to benefit from elevated practitioner engagement during the peak cold and flu period.

• FY26 profitability expected, subject to normal trading conditions.